Arthritis Northwest

Recent papers from Arthritis Northwest

1. Palopegteriparatide in Adults With Hypoparathyroidism: 3.5-Year Results From the Phase 3 PaTHway TrialThe Journal of Clinical Endocrinology & Metabolism · 2026
2. Unity Through Rheumatic Diseases: A Youth-Led Model of Community, Connection, and ChangeThe Journal of Rheumatology · 2026
3. A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s diseaseThe Journal of Prevention of Alzheimer s Disease · 2025
4. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway TrialThe Journal of Clinical Endocrinology & Metabolism · 2024
5. Pos0277 Canakinumab Prophylaxis Without Corticosteroids, Prevented Flares in Patients Initiating Pegloticase With Methotrexate for Uncontrolled Gout: A Prospective, Multicenter, Open Label, Proof-of-Concept, Phase Iv, Clinical TrialAnnals of the Rheumatic Diseases · 2024
6. Pos0938 Canakinumab With or Without Corticosteroids Reduced Gout Flares Associated With Pegloticase Treatment Regardless of the Immunomodulator Used: A Real-World Database StudyAnnals of the Rheumatic Diseases · 2024
7. Naturalistic assessment of everyday multitasking in Parkinson’s disease with and without mild cognitive impairmentThe Clinical Neuropsychologist · 2024
8. Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findingsRheumatology Advances in Practice · 2024
9. Decrease Venous Thromboembolism Without Anticoagulation in Plastic Surgery: The Paradigm of Risk Identification, Risk Modification, and Risk ReductionPlastic Surgery · 2023
10. Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trialDiabetes Obesity and Metabolism · 2023
11. Epidemiology and clinical characteristics of interstitial lung disease in patients with rheumatoid arthritis from the JointMan databaseScientific Reports · 2023
12. Breast Implants Decrease Chest Wall Trauma in Low-speed, Unrestrained Motor Vehicle Crash: An Experimental ModelPlastic & Reconstructive Surgery Global Open · 2023
13. A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month FindingsACR Open Rheumatology · 2023
14. Effectiveness of Neonatal Early Supported Transfer To Home Interventions: Implications For PracticeThe Practising Midwife · 2023
15. Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCEDiabetes Obesity and Metabolism · 2023
16. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trialArthritis Research & Therapy · 2022
17. The Majority of Venous Thromboembolism Events Should Occur in Lower Risk Aesthetic Surgery Patients: A Simulation StudyPlastic & Reconstructive Surgery Global Open · 2022
18. A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety FindingsArthritis & Rheumatology · 2022
19. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label studyArthritis Research & Therapy · 2022
20. Site-Specific Intact N-Linked Glycopeptide Characterization of Prostate-Specific Membrane Antigen from Metastatic Prostate Cancer CellsACS Omega · 2022